Early Alzheimer's Disease
18
6
9
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
33%
6 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (18)
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
A Study to Compare Two Different Sleep Tests in Participants With No Symptoms or Early Symptoms of Alzheimer's Disease
Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Early Alzheimer's Disease
Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
Effect of Transcranial Alternating Current Stimulation(tACS) for Early Alzheimer's Disease
A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD
Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects